CL2021000606A1 - Anticuerpos agonistas contra cd200r y sus usos - Google Patents

Anticuerpos agonistas contra cd200r y sus usos

Info

Publication number
CL2021000606A1
CL2021000606A1 CL2021000606A CL2021000606A CL2021000606A1 CL 2021000606 A1 CL2021000606 A1 CL 2021000606A1 CL 2021000606 A CL2021000606 A CL 2021000606A CL 2021000606 A CL2021000606 A CL 2021000606A CL 2021000606 A1 CL2021000606 A1 CL 2021000606A1
Authority
CL
Chile
Prior art keywords
cd200r
agonist antibodies
antibodies against
gvhd
ibd
Prior art date
Application number
CL2021000606A
Other languages
English (en)
Inventor
Stephen John Demarest
Anja Koester
Payal Mehta
Scott Charles Potter
Diana Isabel Ruiz
Derrick Ryan Witcher
Xiufeng Wu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2021000606A1 publication Critical patent/CL2021000606A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a anticuerpos agonistas anti-CD200R humano, y sus usos para tratar enfermedades tales como dermatitis atópica, urticaria crónica espontánea, alergia, asma, esclerodermia, IBD, SLE, MS, RA, GvHD, o psoriasis.
CL2021000606A 2018-09-14 2021-03-11 Anticuerpos agonistas contra cd200r y sus usos CL2021000606A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862731204P 2018-09-14 2018-09-14

Publications (1)

Publication Number Publication Date
CL2021000606A1 true CL2021000606A1 (es) 2021-09-20

Family

ID=68051977

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000606A CL2021000606A1 (es) 2018-09-14 2021-03-11 Anticuerpos agonistas contra cd200r y sus usos

Country Status (27)

Country Link
US (2) US11319370B2 (es)
EP (1) EP3849667A1 (es)
JP (3) JP7185051B2 (es)
KR (1) KR102705378B1 (es)
CN (2) CN118530360A (es)
AR (1) AR116668A1 (es)
AU (1) AU2019339334B2 (es)
BR (1) BR112021003254A2 (es)
CA (1) CA3112763C (es)
CL (1) CL2021000606A1 (es)
CO (1) CO2021003093A2 (es)
CR (1) CR20210134A (es)
DO (1) DOP2021000040A (es)
EA (1) EA202190530A1 (es)
EC (1) ECSP21017619A (es)
IL (1) IL281442B2 (es)
JO (1) JOP20210048A1 (es)
MA (1) MA53604A (es)
MX (1) MX2021003026A (es)
MY (1) MY196156A (es)
NZ (1) NZ773626A (es)
PE (1) PE20211742A1 (es)
PH (1) PH12021550530A1 (es)
SG (1) SG11202101697YA (es)
TW (1) TWI749367B (es)
WO (1) WO2020055943A1 (es)
ZA (2) ZA202101246B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114555792A (zh) 2019-10-15 2022-05-27 伊莱利利公司 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系
KR20230018425A (ko) 2020-05-29 2023-02-07 23앤드미 인코포레이티드 항-cd200r1 항체 및 이의 사용 방법
PE20251170A1 (es) * 2022-04-06 2025-04-23 Mirobio Ltd Anticuerpos cd200r disenados por ingenieria y usos de estos
CN115458048B (zh) * 2022-09-16 2023-05-26 杭州美赛生物医药科技有限公司 基于序列编解码的抗体人源化方法
WO2024248532A1 (ko) * 2023-06-02 2024-12-05 (주)에임드바이오 항-cd200r1 항체 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2448668A1 (en) * 2001-05-24 2002-11-28 Trillium Therapeutics Inc. Modulation of cd200 receptors
WO2003077947A1 (en) * 2002-03-15 2003-09-25 Schering Corporation Methods of modulating cd200 receptors
WO2007084321A2 (en) * 2006-01-12 2007-07-26 Alexion Pharmaceuticals, Inc. Antibodies to ox-2/cd200 and uses thereof
WO2008079352A2 (en) * 2006-12-22 2008-07-03 Schering Corporation Antibodies to cd200r
CA2786692A1 (en) * 2010-01-11 2011-07-14 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
NZ601580A (en) * 2010-02-11 2014-11-28 Alexion Pharma Inc Therapeutic methods using anti-cd200 antibodies
WO2015057906A1 (en) 2013-10-16 2015-04-23 Janssen Biotech, Inc. Cd200 receptor 1 agonists

Also Published As

Publication number Publication date
ECSP21017619A (es) 2021-04-29
ZA202101246B (en) 2023-04-26
CR20210134A (es) 2021-03-29
NZ773626A (en) 2024-11-29
AR116668A1 (es) 2021-06-02
TWI749367B (zh) 2021-12-11
KR20210044262A (ko) 2021-04-22
US11319370B2 (en) 2022-05-03
BR112021003254A2 (pt) 2021-05-18
CA3112763A1 (en) 2020-03-19
WO2020055943A1 (en) 2020-03-19
CN118530360A (zh) 2024-08-23
TW202024132A (zh) 2020-07-01
EA202190530A1 (ru) 2021-06-21
KR102705378B1 (ko) 2024-09-12
MY196156A (en) 2023-03-17
EP3849667A1 (en) 2021-07-21
PH12021550530A1 (en) 2022-02-14
JOP20210048A1 (ar) 2021-03-11
JP2024105529A (ja) 2024-08-06
CA3112763C (en) 2024-05-14
JP2022500080A (ja) 2022-01-04
AU2019339334B2 (en) 2023-03-09
JP7490025B2 (ja) 2024-05-24
CN112739422B (zh) 2024-05-28
JP2022141959A (ja) 2022-09-29
ZA202204978B (en) 2022-09-28
MX2021003026A (es) 2021-05-27
SG11202101697YA (en) 2021-04-29
AU2019339334A1 (en) 2021-03-18
MA53604A (fr) 2021-12-22
IL281442B2 (en) 2024-03-01
CO2021003093A2 (es) 2021-03-19
JP7185051B2 (ja) 2022-12-06
CN112739422A (zh) 2021-04-30
DOP2021000040A (es) 2021-03-31
PE20211742A1 (es) 2021-09-06
IL281442B1 (en) 2023-11-01
US20220251198A1 (en) 2022-08-11
IL281442A (en) 2021-04-29
US20200087395A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
CL2021000606A1 (es) Anticuerpos agonistas contra cd200r y sus usos
ECSP19029758A (es) Anticuerpos anti-il-33 y usos de los mismos
PH12019500408A1 (en) Asid-alpha glucosidase variants and uses thereof
MX383130B (es) Composiciones que comprenden cepas bacterianas del genero megasphaera y sus usos.
GT201700188A (es) Anticuerpos contra tau y sus usos
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
ZA201902140B (en) Acid-alpha glucosidase variants and uses thereof
NZ750179A (en) Uses of il-13 antagonists for treating atopic dermatitis
MX2023005484A (es) Analogos de carbamoil fenilalaninol y usos de los mismos.
MX391725B (es) Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.
ECSP22041169A (es) Anticuerpos trem2 y usos de estos
MX2017010037A (es) Metodos de tratamiento de enfermedades inflamatorias.
MY202185A (en) Carbamoyl phenylalaninol compounds and uses therof
GB2524648B (en) Pressure regulating valve and method of adjusting damping of the same
TN2018000289A1 (en) Antibodies for il-17c
PH12017500613A1 (en) Improved peptide inhibitors of sodium channels
CO2018007236A2 (es) Reguladores cftr y métodos de uso
MX378112B (es) Anticuerpos que potencian el factor h y sus usos.
PH12017501872A1 (en) Methods of treating diseases
MX2018012410A (es) Metodos para tratar enfermedades inflamatorias.
BR112017006450A2 (pt) vetor adenoviral codificando atonal homólogo-1 de humano (hath1)
RS57693B1 (sr) Aksijalni regulator pritiska gasa indirektnog dejstva
CR20190176A (es) Usos de antagonistas de il-13 para el tratamiento de dermatitis atópica
DOP2019000082A (es) Anticuerpos anti-il-33 y usos de los mismos
BR112017016772A2 (pt) bactérias probióticas recombinantes para uso no tratamento de uma disfunção inflamatória da pele e método para tratá-la